Esophageal cancer

Current Opinion in Gastroenterology

Volumn 15, Issue 4, 1999, Pages 364-369

  Lerut, T ^a   Decker, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOCARCINOMA; ALCOHOL CONSUMPTION; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DYSPLASIA; EARLY CANCER; ENDOSCOPIC THERAPY; ESOPHAGUS CANCER; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; METASTASIS; MOLECULAR BIOLOGY; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 0032770561     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199907000-00016     Document Type: Article

References (41)

1. 1 Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V: Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998, 13(4):356-362.
2. 2 Sharma VK, Chockalingam H, Hornung CA, Vasudeva R, Howden CW: Changing trends in esophageal cancer: a 15-year experience in a single center. Am J Gastroenterol 1998, 93(5):702-705.
3. 3 Granbaek M, Becker U, Johansen D, Tnnesen H, Jensen G, Srensen TI: Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract. Br Med J 1998, 317(7162):844-847. Moderate intake of wine probably does not increase the risk of upper digestive cancer, whereas moderate intake of beer or spirits increase the risk considerably.
4. 4 Sullivan PA, Eisen EA, Woskie SR, Kriebel D, Wegman DH, Hallock MF, Hammond SK, Tolbert PE, Smith TJ, Monson RR: Mortality studies of metalworWng fluid exposure in the automobile industry: VI. A case-control study of esophageal cancer. Am J Ind Med 1998, 34(1):36-48.
5. 5 Morgan G, Vainio H: Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential and non-steroidal anti-inflammatory drugs. Eur J Cancer Prev 1998, 7(3):195-199.
6. 6 Wilson KT, Fu S, Ramanujam KS, Meltzerr SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998, 58(14):2929-2934.
7. 7 Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of oesophageal cancer. Cancer Epidemiol Biomarkers Prev 1998, 7(2):97-102. The risk of cancers of the esophagus and stomach is reduced in users of nonsteroidal anti-inflammatory drugs.
8. 8 Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D: The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998, 93(4):536-541.
9. 9 Streitz JM Jr, Ellis FH, Tilden RL, Erickson RV: Endoscopic surveillance of Barrett's esophagus: a cost effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998, 93(6):911-915. Endoscopic surveillance of patients with Barrett's esophagus compares favorably with the common practice of surveillance mammography to detect early breast cancer.
10. 10 Messmann H, Knuchel R, Endlicher E, Hauser T, Szeimies RM, Kullmann F, Baumler W, Scholmerich J. Photodynamic diagnosis of gastrointestinal precancerous lesions after sensitization with 5-aminolevulinic acid. A pilot study. Dtsch Med Wochenschr 1998, 123(17):515-521. Photodynamic diagnosis makes it possible to visualize precancerous lesions after preceding 5-aminolevulinic sensitization.
11. 11 Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, Van Hillegersberg R, Tilanus HW, Wilson JH, Siersema PD: Biochemical basis of 5 aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998, 78(5):679-682.
12. 12 Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, Lewin KJ, Roth MJ: Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer 1998, 83(2):220-231.
13. 13 Kawahara K, Maekawa T, Okabayashi K, Shiraishi T, Yoshinaga Y, Yoneda S, Hideshima T, Shirakusa T: The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol 1998, 67(3):106-163. Survival in patients with thoracic esophageal cancer involving one or more nodes is poorer than in patients with lesser involvement, the latter reaching survival close to that of patients with no lymph node involvement.
14. 14 Korst RJ, Rusch VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ: Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998, 115(3):660-670.
15. 15 Natsugoe S, Baba M, Yoshinaka H, Kijima F, Shimada M, Shirao K, Kusano C, Fukumoto T, Mueller J, Aikou T: Mucosal squamous cell carcinoma of the esophagus: a clinicopathologic study of 30 cases. Oncology 1998, 55(3):235-241. It is critical to distinguish among M1, M2, and M3 to plan treatment strategies.
16. 16 Pham T, Roach E, Falk GL, Chu J, Ngu MC, Jones DB: Staging of oesophageal carcinoma by endoscopic ultrasound: preliminary experience. Aust N Z J Surg 1998, 68(3):209-212. Endoscopic ultrasonography has reasonable accuracy for staging.
17. 17 Vickers J: Role of endoscopic ultrasound in the preoperative assessment of patients with oesophageal cancer. Ann R Coll Surg Engl 1998, 80(4):233-239
18. 18 Hunerbein M, Dohmoto M, Haensch W, Schlag PM. Endosonographyguided biopsy of mediastinal and pancreatic tumors. Endoscopy 1998, 30(1):32-36. Biopsy guided by endoscopic ultrasonography considerably improves the diagnostic value of endosonography.
19. 19 Lerut T: Esophageal surgery at the end of the millennium. J Thorac Cardiovasc Surg 1998, 116(1):1-20.
20. 20 Doldi SB, Lattuada E, Zappa MA, Cioffi U, Pieri G, Massari M, De Simone M, Peracchia A: Ultrasonographic evaluation of the cervical lymph nodes in preoperative staging of esophageal neoplasms. Abdom Imaging 1998, 23(3):275-277.
21. 21 Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998, 78(4):521-527. Positron emission tomography has a higher sensitivity for nodal and distal metastasis and a higher accuracy for determining resectability than computed tomography.
22. 22 Rankin SC, Taylor H, Cook GJ, Mason R: Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998, 53(9):659-665.
23. 23 Ng CS, Husband JE, Mac Vicar AD, Ross P, Cunningham DC: Correlation of CT with histopathological findings in patients with gastric and gastrooesophageal carcinoma following neoadjuvant chemotherapy. Clin Radiol 1998, 53(6):422-427.
24. 24 Isenberg G, Chak A, Canto MI, Levitan N, Clayman J, Pollack BJ, Sivak MV Jr: Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998, 48(2):158-163.
25. 25 Hosch SB, Izbicki JR, Rehders A, Passlick B, Broelsch CE, Pantel K: Early lymphatic dissemination of tumor cells in esophageal cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1997, 38:A3474.
26. 26 Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, Siewert JR: Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998, 833(5):858-866.
27. 27 Savary JF, Grosjean P, Monnier P, Fontolliet C, Wagnieres G, Braichotte D, van den Bergh H: Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. Endoscopy 1998, 309(3):258-265.
28. 28 Gossner L, Stolte M, Sroka R, May A, Hahn EG, Ell C: Photodynamic therapy of early squamous epithelial carcinomas and severe squamous epithelial dysplasias of the esophagus with 5-aminolevulinic acid. Z Gastroenterol 1998, 36(1):19-26. Severe dysplasia and superficial mucosal cancer of the esophagus can be eradicated by 5-aminnolevulinic acid photodynamic therapy.
29. 29 Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma. Am J Pathol 1998, 152(1):135-144. This is an excellent overview of the state of understanding of the role of cadherin and catenin in the Barrett's esophagus-dysplasia-adenocarcinoma sequence.
30. 30 Busatto G, Shiao Yh, Parenti AR, Baffa R, Ruol A, Plebani M, Rugge M: p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Pathol 1998, 51(2):80-84.
31. 31 Roncalli M, Basari S, Marchetti A, Buttitta FF, Bossi P, Graziani D, Peracchia A, Bonavina L, Viale G, Coggi G: Cell cycle related gene abnormalities and product expression in esophageal carcinoma. Lab Invest 1998, 78(9):1049-1057.
32. 32 Ribeiro U, Finkelstein SD, Safatle AV, Landreneau RJ, Clark MR, Bakker A, Swalsky PA, Gooding WE, Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998, 83(1):7-18. Histopathologic/genetic analysis is a better determinant of p53 mutational damage than immunohistochemistry alone and can be used as prognostic marker, p53 genotyping may define a subset of patients who respond to chemotherapy or radiotherapy.
33. 33 Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR: Problems with immunohistochemical staining: the effect of fixation and variations in the methods of evaluation. Br J Cancer 1994, 69(1):26-31.
34. 34 Morgan RJ, Newcomb PV, Bailey M, Hardwick RH, Alderson D: Loss of heterozygosity at microsatellite marker sites for tumor suppressor genes in oesophageal carcinoma, Eur J Surg Oncol 1998, 24(1):34-37. Allelic deletions of p53, p16, and Rb are common in esophageal carcinoma and seem to be important in the development of this disease.
35. 35 Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H: p53 alterations in oesophageal cancer: association with clinopathological features, risk factors, and survival. Mol Pathol 1998, 51(2):71-79.
36. 36 Cawley HM, Meltzer SJ, Virna M, De Benedetti G, Hollstein MC, Muehlbauer KR, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrel J, Salabes A, Bartsch H, Trivers GE: Anti-P53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterol 1998, 115(1):19-27.
37. 37 Rigberg D, Kim FS, Blinman TA, Cole MA, Lane JS, So J, McFadden DW: p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res 1998, 76(2):137-142. This is the first report of radiation-induced p21 expression in esophageal cell lines.
38. 38 Morita S, Yano M, Tsujinaka T, Ogawa A, Taniguchi M, Kaneko, Shiozaki H, Doki Y, Ione M, Monden M: Association between genetic polymorphisms of glutathiaone S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous cell carcinoma of the esophagus. Int J Cancer 1998, 79(5):517-520.
39. 39 Uchida S, Shimado Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Arri S, Imamura M: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998, 77(10):1704-1709. This study indicates the correlation between p53 mutation and vascular endothelial growth factor promoting angiogenesis.
40. 40 Takebayashi Y, Natugoe S, Baba M, Fukumoto T, Takao S, Akiba S, Akiyama S, Aikou T: Angiogenesis in esophageal squamous cell carcinoma. Oncol Rep 1998, 5(2):401-404.
41. 41 Brachman RK, Yu K, Eby Y, Pavletich NB, Baeke JD: Genetic selection of intragenetic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 1998, 17:1847-1859. Emphasizes the possibility of genetic manipulation as a framework of new forms of anticancer therapy.